683 Capital Management, LLC Galmed Pharmaceuticals Ltd. Transaction History

683 Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$3.22 - $6.08 $2.52 Million - $4.75 Million	-781,820 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$3.3 - $6.84 $59,994 - $124,351	-18,180 Reduced 2.27%	781,820 $2.71 Million
Q4 2019 Feb 14, 2020	SELL	$3.61 - $6.75 $2.01 Million - $3.76 Million	-556,356 Reduced 41.02%	800,000 $4.62 Million
Q3 2019 Nov 14, 2019	BUY	$4.62 - $7.11 $29,364 - $45,191	6,356 Added 0.47%	1,356,356 $6.48 Million
Q2 2018 Aug 14, 2018	BUY	$5.04 - $17.96 $3.53 Million - $12.6 Million	700,705 Added 107.92%	1,350,000 $16.1 Million

Q4 2017 Feb 14, 2018	BUY	$6.78 - $9.32 $678,000 - $932,000	100,000 Added 18.21%	649,295 $5.94 Million
Q3 2017 Nov 14, 2017	BUY	$7.36 - $9.29 $845,774 - $1.07 Million	114,915 Added 26.45%	549,295 $5.02 Million
Q4 2016 Dec 07, 2017	BUY	N/A	434,380	434,380 $1.53 Million

Ticker GLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,088,400
Market Cap $7.53M
Description
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.